Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer

R. Borovik; R. Epelbaum; Y. Cohen; E. Robinson

Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer

R. Borovik, R. Epelbaum, Y. Cohen, E. Robinson

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.

Original language	English
Pages (from-to)	517-518
Number of pages	2
Journal	Cancer Treatment Reports
Volume	70
Issue number	4
State	Published - 1 Jan 1986
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{a120ce63a28a46d287690931cfb8f25c,

title = "Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer",

abstract = "Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.",

author = "R. Borovik and R. Epelbaum and Y. Cohen and E. Robinson",

year = "1986",

month = jan,

day = "1",

language = "English",

volume = "70",

pages = "517--518",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer

AU - Borovik, R.

AU - Epelbaum, R.

AU - Cohen, Y.

AU - Robinson, E.

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.

AB - Thirty-seven patients with disseminated breast cancer refractory to previous therapy were treated with a combination of mitomycin, doxorubicin, and vinblastine (MAV). One complete and eight partial responses were achieved, with an overall response rate of 24.3%. The median duration of response was 5+ months. The MAV regimen had generally moderate but acceptable toxicity. This study indicates that the MAV combination is no better than doxorubicin given as a single agent.

UR - http://www.scopus.com/inward/record.url?scp=0022623738&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0022623738

VL - 70

SP - 517

EP - 518

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -

Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this